Clinical Trial Update: Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating dasatinib with low-intensity chemotherapy for Philadelphia chromosome–positive acute lymphoblastic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: Versailles Hospital | Conditions: Leukemia, Lymphoblastic, Acute | Phase 2 | Status: COMPLETED